US Bancorp
ADPT icon

US Bancorp’s Adaptive Biotechnologies ADPT Stock Holding History

US Bancorp’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.38M Buy
157,346
+40,890
+35% +$626K ﹤0.01% 734
2026
Q1 		$1.62M Sell
116,456
-15,022
-11% -$239K ﹤0.01% 953
2025
Q4 		$2.14M Buy
131,478
+4,325
+3% +$70.6K ﹤0.01% 861
2025
Q3 		$1.9M Buy
127,153
+8,738
+7% +$106K ﹤0.01% 895
2025
Q2 		$1.38M Sell
118,415
-15,636
-12% -$142K ﹤0.01% 1003
2025
Q1 		$996K Buy
134,051
+14,764
+12% +$113K ﹤0.01% 1103
2024
Q4 		$715K Sell
119,287
-43,819
-27% -$242K ﹤0.01% 1279
2024
Q3 		$835K Buy
163,106
+71,065
+77% +$310K ﹤0.01% 1218
2024
Q2 		$333K Sell
92,041
-9,063
-9% -$28.8K ﹤0.01% 1733
2024
Q1 		$325K Sell
101,104
-9,873
-9% -$38.2K ﹤0.01% 1762
2023
Q4 		$544K Buy
110,977
+105,077
+1,781% +$479K ﹤0.01% 1439
2023
Q3 		$32.2K Sell
5,900
-1,042
-15% -$6.89K ﹤0.01% 2651
2023
Q2 		$46.6K Sell
6,942
-48
-0.7% -$357 ﹤0.01% 2535
2023
Q1 		$61.7K Buy
6,990
+362
+5% +$3.19K ﹤0.01% 2410
2022
Q4 		$50.6K Sell
6,628
-3,938
-37% -$30.6K ﹤0.01% 2519
2022
Q3 		$75K Sell
10,566
-24,744
-70% -$233K ﹤0.01% 2316
2022
Q2 		$286K Sell
35,310
-13,282
-27% -$117K ﹤0.01% 1717
2022
Q1 		$674K Buy
48,592
+157
+0.3% +$2.47K ﹤0.01% 1384
2021
Q4 		$1.36M Buy
48,435
+9,233
+24% +$283K ﹤0.01% 1077
2021
Q3 		$1.33M Buy
39,202
+1,679
+4% +$60.7K ﹤0.01% 1048
2021
Q2 		$1.53M Buy
37,523
+9,906
+36% +$385K ﹤0.01% 995
2021
Q1 		$1.11M Buy
27,617
+3,009
+12% +$163K ﹤0.01% 1079
2020
Q4 		$1.46M Sell
24,608
-264
-1% -$13.6K ﹤0.01% 940
2020
Q3 		$1.21M Buy
24,872
+1,992
+9% +$83.7K ﹤0.01% 914
2020
Q2 		$1.11M Buy
22,880
+14,412
+170% +$525K ﹤0.01% 919
2020
Q1 		$235K Buy
8,468
+8,467
+846,700% +$236K ﹤0.01% 1576
2019
Q4 		$0 Buy
+1
New +$29 ﹤0.01% 3640

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

US Bancorp's ADPT Position: Q2 2026 in Review

US Bancorp increased its Adaptive Biotechnologies (ADPT) stake by 35% in Q2 2026, buying an estimated $626K and bringing the position to 157,346 shares worth $3.38M. The position accounts for ﹤0.01% of the portfolio, ranked #734.

US Bancorp first reported a position in ADPT in Q4 2019 and has held it in 27 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • US Bancorp held 157,346 shares of Adaptive Biotechnologies worth $3.38M as of Q2 2026.
  • US Bancorp bought 40,890 Adaptive Biotechnologies shares in Q2 2026, an estimated $626K.
  • Adaptive Biotechnologies made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #734 holding.
  • US Bancorp first reported a position in Adaptive Biotechnologies in Q4 2019 and has held it in 27 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.